Long-term health care interruptions among HIV-positive patients in Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 1, 2013, Pages

  Mills, Edward J ^a,b   Funk, Anna ^a   Kanters, Steve ^a   Kawuma, Esther ^c   Cooper, Curtis ^d   Mukasa, Barbara ^c   Odit, Mary ^c   Karamagi, Yvonne ^c   Mwehire, Daniel ^c   Nachega, Jean ^e   Yaya, Sanni ^a   Featherstone, Amber ^a   Ford, Nathan ^f  

^a UNIVERSITY OF OTTAWA   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MILDMAY UGANDA   (Uganda)

^d UNIVERSITY OF OTTAWA   (Canada)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

adherence; antiretroviral therapy; health systems; HIV AIDS; loss to follow up; retention

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SEXUAL BEHAVIOR; TREATMENT FAILURE; UGANDA;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LOST TO FOLLOW-UP; MALE; MEDICATION ADHERENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UGANDA;

EID: 84876297502     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828a3fb8     Document Type: Article

References (27)

1. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-216.
2. Mills EJ, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS. 2011;25:851-855.
3. Mills EJ, Bakanda C, Birungi J, et al. The prognostic value of baseline CD4+ cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting. AIDS. 2012;26:1425-1429.
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
5. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051-1058.
6. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4:e298.
7. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(suppl 1):1-15.
8. Moore DM, Zhang W, Yip B, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010;11:299-307.
9. Reynolds SJ, Kityo C, Hallahan CW, et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One. 2010;5:e10307.
10. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS SocietyUSA panel. JAMA. 2008;300:555-570.
11. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007; 21:965-971.
12. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573.
13. Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20:1053-1056.
14. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health. 2011;16:1297-1313.
15. Funk A, Kanters S, Nansubuga M, et al. Cohort profile: the MUg observational cohort. Int J Epidemiol. 2012;41:1594-1594.
16. Ministry of Health. National Antiretroviral Treatment and Care Guidelines for Adults and Children. Kampala, Uganda: Earnest Publishers; 2010.
17. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974;19:716-723.
18. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute; 1995.
19. Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7:234-244.
20. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53:405-411.
21. Kranzer K, Ford N. Unstructured treatment interruption of antiretrovi-ral therapy in clinical practice: a systematic review. Trop Med Int Health. 2011;16:1297-1313.
22. Decroo T, Telfer B, Biot M, et al. Distribution of antiretroviral treatment through self-forming groups of patients in Tete province, Mozambique. J Acquir Immune Defic Syndr. 2011;56:e39-e44.
23. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25:825-834.
24. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838-1845.
25. Cohen MS, Muessig KE, Smith MK, et al. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS. 2012;26: 1585-1598.
26. Cohen MS, Dye C, Fraser C, et al. HIV treatment as prevention: debate and commentary-will early infection compromise treatment-as-prevention strategies? PLoS Med. 2012;9:e1001232.
27. Jaffar S, Amuron B, Foster S, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet. 2009; 374:2080-2089.